[Stenoptin in angina pectoris (author's transl)].
In a placebo-controlled double blind study 20 patients suffering from angina pectoris were treated with Stenoptin. The patients had 5 attacks at least per week and consumed 5 chwable nitrocapsules and more. Criteria of success were consumption of chewable nitrocapsules and frequency of attacks. During a 7 day preobservation period the patients received a placebo identical with Stenoptin and 20 chewable nitrocapsules. The study lasted for 8 weeks. The dose was 1 tablet 3 times per day. The attacks of the active substance group were reduced from 11 to 2 on the average, and the nitro-consumption from 16 to 2 per week. In the placebo group frequency of attack slightly increased from 10 to 11. In the active substance group the dose could be reduced to 1 tablet twice per day. The placebo group was treated with 1 Stenoptin tablet 3 times per day for another 8 weeks. Subsequently 1 tablet twice per day sufficed. Transient, nitro-induced headache occurred only in 3 test persons. Stenoptin did not cause side effects and was very effective in serious types of angina pectoris.
D000328:Adult; D000368:Aged; D000787:Angina Pectoris / Q000188:drug therapy* / Q000378:metabolism; D002118:Calcium / Q000037:antagonists & inhibitors; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007548:Isosorbide Dinitrate / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009574:Nitro Compounds / Q000627:therapeutic use; D010101:Oxygen Consumption; D014700:Verapamil / Q000627:therapeutic use*
D009574:Nitro Compounds; D014700:Verapamil; D007548:Isosorbide Dinitrate; D002118:Calcium
Stenoptin bei Angina pectoris.